# ARID2

## Overview
ARID2 is a gene that encodes the AT-rich interaction domain 2 protein, a critical component of the SWI/SNF chromatin remodeling complex, specifically the PBAF subclass. This protein is involved in modulating chromatin structure, thereby influencing gene expression by altering chromatin accessibility. The ARID2 protein is characterized by several domains, including an ARID domain, an RFX-like DNA-binding domain, and a tandem C2H2 zinc finger domain, which contribute to its DNA-binding capabilities (Korn2022Structures; Loesch2020ARID2). Functionally, ARID2 plays a significant role in DNA repair processes, particularly in the nucleotide excision repair pathway, and is essential for the expression of metastasis inhibitors and adhesion molecules (Moreno2020ARID2deficiency; Moreno2021ARID2). Clinically, mutations in the ARID2 gene are associated with intellectual disabilities and various cancers, highlighting its importance in maintaining genomic stability and proper gene expression regulation (Gazdagh2019Extending; Loesch2020ARID2).

## Structure
The ARID2 protein is a component of the PBAF chromatin remodeling complex and is characterized by several distinct domains. It contains an N-terminal ARID domain, which is involved in DNA binding and protein-protein interactions, although it binds DNA without sequence specificity (Korn2022Structures; Loesch2020ARID2). The ARID domain is approximately 100 amino acids long and features a modified helix-turn-helix motif (WILSKER2005Nomenclature). ARID2 also includes an RFX-like DNA-binding domain with a winged-helix type motif and a tandem C2H2 zinc finger domain located at the C-terminus, which contribute to its DNA-binding capabilities (Xu2012Essential; Korn2022Structures).

The protein has a proline and glutamine-rich domain in the middle, though its function is not fully understood (Loesch2020ARID2). ARID2 is unique among its subunits for having a short half-life, and its expression is crucial for the stability and recruitment of other PBAF-specific subunits (Loesch2020ARID2). While the context does not provide detailed information on the primary, secondary, tertiary, or quaternary structures, it is known that ARID2 may undergo post-translational modifications such as phosphorylation and has multiple splice variant isoforms, contributing to its functional diversity.

## Function
The ARID2 gene encodes a protein that is a component of the SWI/SNF chromatin remodeling complex, specifically the PBAF subclass. This complex plays a crucial role in modulating chromatin structure, thereby regulating gene expression by altering chromatin accessibility. In healthy cells, ARID2 is involved in maintaining a closed chromatin structure around promoters of specific genes to repress their expression, while keeping an open chromatin structure around enhancers of positively regulated genes to facilitate their expression (Xu2012Essential; Moreno2020ARID2deficiency).

ARID2 is essential for the expression of metastasis inhibitors like MTSS1 and adhesion molecules such as SDK1, as it maintains an open chromatin structure at their enhancers (Moreno2021ARID2). It also plays a significant role in DNA repair processes, particularly in the nucleotide excision repair (NER) pathway, by facilitating the recruitment of key components like XPG to DNA-damaged sites (Oba2017ARID2). This function is critical for maintaining genomic stability and proper gene expression regulation in healthy cells (Moreno2021ARID2). ARID2's involvement in these molecular processes underscores its importance in cellular differentiation and development (Xu2012Essential).

## Clinical Significance
Mutations in the ARID2 gene are associated with a range of intellectual disabilities and syndromic conditions. ARID2-related intellectual disability is characterized by features such as coarse facial features, hypotonia, behavioral problems, and hypoplasia of the fifth finger or toenails, with significant overlap with Coffin-Siris syndrome (CSS) (Gazdagh2019Extending). ARID2 mutations, including de novo truncating mutations and deletions, have been identified in patients exhibiting CSS-like phenotypes (Bramswig2017Heterozygosity). These mutations are linked to a spectrum of neurodevelopmental disorders, including those classified under SWI/SNF-related intellectual disability disorders (SSRIDD) (Kang2020Association).

In addition to intellectual disabilities, ARID2 mutations are implicated in various cancers, including hepatocellular carcinoma (HCC) and melanoma. In HCC, ARID2 mutations are characterized by frameshift-inducing insertions or deletions, nonsense mutations, and splice-site mutations, which are often correlated with CTNNB1 mutations and are mutually exclusive with TP53 mutations (Loesch2020ARID2). ARID2 acts as a tumor suppressor, and its loss can lead to impaired DNA damage response and aberrant transcriptional regulation, contributing to tumorigenesis (Loesch2020ARID2). ARID2 mutations are also associated with cancer cell immunotherapy resistance, enhancing sensitivity to T cell-mediated killing (Loesch2020ARID2).

## Interactions
ARID2 is a component of the SWI/SNF chromatin remodeling complex, specifically within the PBAF subset, and participates in various protein-protein interactions. It interacts with RAD51, a protein involved in the repair of double-strand breaks in DNA, facilitating RAD51's recruitment to these sites during homologous recombination repair (Loesch2020ARID2). ARID2 also interacts with E2F1, a transcription factor, to repress cyclin D1/E1 by dissociating E2F1 and RNA polymerase II from the promoters of CCND1 and CCNE1, thereby controlling cell proliferation (Loesch2020ARID2).

In the context of DNA damage response, ARID2 is involved in the recruitment of XPG, a component of the nucleotide excision repair mechanism, to DNA-damaged sites, although it does not affect the recruitment of XPC (Oba2017ARID2). This interaction is crucial for maintaining genomic stability and preventing tumorigenesis (Oba2017ARID2).

ARID2 also plays a role in osteoblast differentiation by directly occupying the promoters of genes such as Bmp4 and Fgfr2, which are essential for osteogenic gene activation (Xu2012Essential). It is necessary for the recruitment of RNA polymerase II to the Alpl promoter, facilitating gene activation during osteoblast differentiation (Xu2012Essential).


## References


[1. (Bramswig2017Heterozygosity) Nuria C. Bramswig, O. Caluseriu, H.-J. Lüdecke, F. V. Bolduc, N. C. L. Noel, T. Wieland, H. M. Surowy, H.-J. Christen, H. Engels, T. M. Strom, and D. Wieczorek. Heterozygosity for arid2 loss-of-function mutations in individuals with a coffin–siris syndrome-like phenotype. Human Genetics, 136(3):297–305, January 2017. URL: http://dx.doi.org/10.1007/s00439-017-1757-z, doi:10.1007/s00439-017-1757-z. This article has 51 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00439-017-1757-z)

2. (Moreno2020ARID2deficiency) ARID2deficiency promotes tumor progression and is associated with higher sensitivity to PARP inhibition in lung cancer. This article has 2 citations.

[3. (Oba2017ARID2) Atsushi Oba, Shu Shimada, Yoshimitsu Akiyama, Taketo Nishikawaji, Kaoru Mogushi, Hiromitsu Ito, Satoshi Matsumura, Arihiro Aihara, Yusuke Mitsunori, Daisuke Ban, Takanori Ochiai, Atsushi Kudo, Hiroshi Asahara, Atsushi Kaida, Masahiko Miura, Minoru Tanabe, and Shinji Tanaka. Arid2 modulates dna damage response in human hepatocellular carcinoma cells. Journal of Hepatology, 66(5):942–951, May 2017. URL: http://dx.doi.org/10.1016/j.jhep.2016.12.026, doi:10.1016/j.jhep.2016.12.026. This article has 52 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.jhep.2016.12.026)

[4. (Loesch2020ARID2) Robin Loesch, Linda Chenane, and Sabine Colnot. Arid2 chromatin remodeler in hepatocellular carcinoma. Cells, 9(10):2152, September 2020. URL: http://dx.doi.org/10.3390/cells9102152, doi:10.3390/cells9102152. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells9102152)

[5. (Kang2020Association) Eungu Kang, Minji Kang, Younghee Ju, Sang-Joon Lee, Yong-Seok Lee, Dong-Cheol Woo, Young Hoon Sung, In-Jeoung Baek, Woo Hyun Shim, Woo-Chan Son, In Hee Choi, Eul-Ju Seo, Han-Wook Yoo, Yong-Mahn Han, and Beom Hee Lee. Association between arid2 and ras-mapk pathway in intellectual disability and short stature. Journal of Medical Genetics, 58(11):767–777, October 2020. URL: http://dx.doi.org/10.1136/jmedgenet-2020-107111, doi:10.1136/jmedgenet-2020-107111. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmedgenet-2020-107111)

[6. (Gazdagh2019Extending) Gabriella Gazdagh, Moira Blyth, Ingrid Scurr, Peter D. Turnpenny, Sarju G. Mehta, Ruth Armstrong, Meriel McEntagart, Ruth Newbury-Ecob, Edward S. Tobias, and Shelagh Joss. Extending the clinical and genetic spectrum of arid2 related intellectual disability. a case series of 7 patients. European Journal of Medical Genetics, 62(1):27–34, January 2019. URL: http://dx.doi.org/10.1016/j.ejmg.2018.04.014, doi:10.1016/j.ejmg.2018.04.014. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2018.04.014)

[7. (Korn2022Structures) Sophie Marianne Korn and Andreas Schlundt. Structures and nucleic acid-binding preferences of the eukaryotic arid domain. Biological Chemistry, 403(8–9):731–747, February 2022. URL: http://dx.doi.org/10.1515/hsz-2021-0404, doi:10.1515/hsz-2021-0404. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/hsz-2021-0404)

[8. (WILSKER2005Nomenclature) D WILSKER, L PROBST, H WAIN, L MALTAIS, P TUCKER, and E MORAN. Nomenclature of the arid family of dna-binding proteins. Genomics, 86(2):242–251, August 2005. URL: http://dx.doi.org/10.1016/j.ygeno.2005.03.013, doi:10.1016/j.ygeno.2005.03.013. This article has 129 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ygeno.2005.03.013)

[9. (Xu2012Essential) Fuhua Xu, Stephen Flowers, and Elizabeth Moran. Essential role of arid2 protein-containing swi/snf complex in tissue-specific gene expression. Journal of Biological Chemistry, 287(7):5033–5041, February 2012. URL: http://dx.doi.org/10.1074/jbc.m111.279968, doi:10.1074/jbc.m111.279968. This article has 59 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m111.279968)

[10. (Moreno2021ARID2) Thaidy Moreno, Beatriz Monterde, Laura González-Silva, Isabel Betancor-Fernández, Carlos Revilla, Antonio Agraz-Doblas, Javier Freire, Pablo Isidro, Laura Quevedo, Rosa Blanco, Santiago Montes-Moreno, Laura Cereceda, Aurora Astudillo, Berta Casar, Piero Crespo, Cristina Morales Torres, Paola Scaffidi, Javier Gómez-Román, Eduardo Salido, and Ignacio Varela. Arid2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer. Oncogene, 40(16):2923–2935, March 2021. URL: http://dx.doi.org/10.1038/s41388-021-01748-y, doi:10.1038/s41388-021-01748-y. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-021-01748-y)